Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure

Bone Marrow Transplantation

Volumn 49, Issue 11, 2014, Pages 1371-1375

  Breitkreutz, I ^a,b   Heiss, C ^a   Perne, A ^a   Beimler, J ^a   Jager D ^b   Egerer, G ^a   Ho, A D ^a   Neben, K ^a   Zeier, M ^a   Goldschmidt, H ^a,b   Raab, M S ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; END STAGE RENAL DISEASE; EVENT FREE SURVIVAL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INDUCTION CHEMOTHERAPY; LENGTH OF STAY; MAINTENANCE THERAPY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; AGED; AUTOGRAFT; DISEASE FREE SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MORTALITY; RENAL REPLACEMENT THERAPY; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AUTOGRAFTS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 84909969098     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.165     Document Type: Article

References (21)

1. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219-9226.
2. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in. 94. patients from a single institution. Arch Intern Med 1998; 158: 1889-1893.
3. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175-181.
4. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. Mayo Clinic Proc 2003; 78: 21-33.
5. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27-33.
6. Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of. 20. cases. Br J Haematol 1995; 91: 854-859.
7. Raab MS, Breitkreutz I, Hundemer M, Benner A, Klaus J, Hegenbart U et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006; 91: 1555-1558.
8. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822-829.
9. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109: 2604-2606.
10. Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M et al. Lenalidomide and dexamethasone for the treatment of refractory/ relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 2010; 85: 1-5.
11. Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007; 92: 1411-1414.
12. Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 2010; 84: 223-228.
13. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
14. Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, de Meester J et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant 2010; 25: 1200-1206.
15. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 812-816.
16. Glavey SV, Gertz MA, Dispenzieri A, Kumar S, Buadi F, Lacy M et al. Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplant 2013; 48: 1543-1547.
17. Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia 2013; 27: 423-429.
18. Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 2010; 25: 419-426.
19. Sinisalo M, Silvennoinen R, Wirta O. High cut-off hemodialysis and bortezomibbased therapy to rescue kidneys in myeloma-dependent cast nephropathy. Am J Hematol 2012; 87: 640.
20. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4: 745-754.
21. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008; 73: 1282-1288.